Sjogren’s Syndrome – Landscape & Forecast – Disease Landscape & Forecast

Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands; the disease may occur alone (primary SS) or with a comorbid autoimmune condition (secondary SS). Symptomatic therapies to treat dry eyes, dry mouth, and/or specific extraglandular manifestations are the cornerstone of disease management. Systemic manifestations are most often treated with hydroxychloroquine or, in severe cases, systemic immunomodulators (e.g., azathioprine, methotrexate). Therapies with disease-modifying potential are in development for SS (e.g., Novartis’s iscalimab and ianalumab and Horizon Therapeutic’s dazodalibep), targeting key pathways believed to drive pathological processes in the disease. These putative disease-modifying therapies have the potential to transform the management of SS, although SS is an indication in which such success has historically been a challenge.

Questions answered

  • How large is the SS population and how will its size change over time?
  • How is SS currently managed? What are the current treatments, and what drives their use?
  • Which unfulfilled clinical needs are the most pressing?
  • Which pipeline products are the most promising, and what sales might they garner in the SS market? What therapies of note are progressing in earlier phases?
  • What clinical roles will Novartis’s iscalimab and ianalumab, and Horizon Therapeutics’ dazodalibep play in the evolving SS treatment landscape?
  • What are the drivers of and constraints in the SS market, and how will the market evolve through 2032?

Content highlights

  • Geographies: United States and EU5.
  • Primary research: Six country-specific interviews with thought-leading SS specialists supported by survey data collected for this study.
  • Epidemiology: Diagnosed and drug-treated prevalent cases of SS by country, diagnosed prevalence by subtype.
  • Forecast: Drug-level sales and patient share of key SS therapies through 2032.
  • Emerging therapies: Phase 3/PR: 1 drug; Phase 2: 7+ drugs; coverage of select early-phase products.

Product description

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Niche & Rare Disease Landscape & Forecast introduces a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports